Instituto Portugues de Oncologia de Coimbra Francisco Gentil, EPE (IPO, Coimbra)

Coimbra 3000-075

0 studies enrolling now · 1 studies all time

What they study most

HER2 Positive Breast Cancer

Studies at this site

• A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer — Running, not enrolling